Ocrelizumab biosimilar - Celltrion
Alternative Names: CT-P53Latest Information Update: 03 Jan 2024
At a glance
- Originator Celltrion
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Multiple sclerosis
Most Recent Events
- 03 Jan 2024 Phase-III clinical trials in Multiple sclerosis (Second-line therapy or greater) in Poland (IV) (Celltrion pipeline; January 2024) (NCT05906992)
- 21 Jun 2023 Celltrion plans a phase III trial for Multiple sclerosis (Second-line therapy or greater) in USA (IV) in December 2023 (NCT05906992)
- 21 Jun 2023 Preclinical trials in Multiple sclerosis in South Korea (IV) before May 2023